These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 22426750)
1. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Shin CR; Kim MO; Li D; Bleesing JJ; Harris R; Mehta P; Jodele S; Jordan MB; Marsh RA; Davies SM; Filipovich AH Bone Marrow Transplant; 2012 Nov; 47(11):1428-35. PubMed ID: 22426750 [TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M; Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
5. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
6. Impact of conditioning on outcome of hematopoietic stem cell transplantation for wiskott-Aldrich syndrome. Stepensky P; Krauss A; Goldstein G; Zaidman I; Elhasid R; Bielorai B; Somech R; Or R; Stein J; Revel-Vilk S; Weintraub M J Pediatr Hematol Oncol; 2013 Aug; 35(6):e234-8. PubMed ID: 23389496 [TBL] [Abstract][Full Text] [Related]
7. [Impact of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia]. ZHANG Y; CHEN YK; FAN ZP; XU D; JIANG QL; SUN J; LIU QF Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):438-42. PubMed ID: 21421478 [TBL] [Abstract][Full Text] [Related]
8. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002 [TBL] [Abstract][Full Text] [Related]
10. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255 [TBL] [Abstract][Full Text] [Related]
11. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465 [TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
13. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome. Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369 [TBL] [Abstract][Full Text] [Related]
14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257 [TBL] [Abstract][Full Text] [Related]
15. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]